DR. CHRISTOPHER NORMAN VAUGHN M.D. NPI 1851322499

NPI Details

DR. Christopher Norman Vaughn, M.D. is a hematology and oncology internal medicine in Fredericksburg, VA with 24 years of experience. The provider is an internist doctor of osteopathy that specializes in the treatment of the combination of hematology and oncology disorders. A doctor of osteopathy that is board eligible/certified by the American Osteopathic Board of Internal Medicine WAS able to obtain a Certificate of Special Qualifications in the field of Hematology and Oncology. The Certificate is NO longer offered. DR. Christopher Norman Vaughn, M.D. NPI is 1851322499. The provider is registered as an individual entity type.

The NPPES NPI record indicates the provider is a male.

Education
Medical School: MEDICAL UNIVERSITY OF SOUTH CAROLINA COLLEGE OF MEDICINE
Graduation Year:2002

The provider's business location address is:

231 PARK HILL DR
FREDERICKSBURG, VA
ZIP 22401-361
Phone: (540) 371-0079
Fax: (540) 371-4254

The NPI 1851322499 is registered in the Medicare Provider, Enrollment, Chain and Ownership System (PECOS). The provider is legally eligible to order and refer Part B (Clinical Laboratory and Imaging), Durable Medical Equipment, Part A Home Health Agency (HHA), Power Mobility Devices.

The following top HCPCS codes were publicly reported for this provider under the Medicare program for the year 2016. The reported codes are based on the top codes for each available Medicare specialty, excluding evaluation and management codes.

• Injection, ferric carboxymaltose, 1 mg (HCPCS:J1439)
• Injection, pembrolizumab, 1 mg (HCPCS:J9271)
• Injection, aprepitant, 1 mg (HCPCS:J0185)
• Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS:Q5110)
• Injection, oxaliplatin, 0.5 mg (HCPCS:J9263)
• Injection, azacitidine, 1 mg (HCPCS:J9025)
• Injection, denosumab, 1 mg (HCPCS:J0897)
• Injection, paclitaxel protein-bound particles, 1 mg (HCPCS:J9264)
• Injection, nivolumab, 1 mg (HCPCS:J9299)
• Injection, daratumumab, 10 mg and hyaluronidase-fihj (HCPCS:J9144)
• Injection, dexamethasone sodium phosphate, 1 mg (HCPCS:J1100)
• Injection, paclitaxel, 1 mg (HCPCS:J9267)
• Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units (HCPCS:Q5106)
• Injection, atezolizumab, 10 mg (HCPCS:J9022)
• Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg (HCPCS:J1568)
• Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count (HCPCS:85025)
• Injection, lanreotide, 1 mg (HCPCS:J1930)
• Injection, bortezomib (velcade), 0.1 mg (HCPCS:J9041)
• Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg (HCPCS:Q5107)
• Insertion of needle into vein for collection of blood sample (HCPCS:36415)
• Injection, palonosetron hcl, 25 mcg (HCPCS:J2469)
• Blood test, comprehensive group of blood chemicals (HCPCS:80053)
• Injection, atropine sulfate, 0.01 mg (HCPCS:J0461)
• Magnesium level (HCPCS:83735)
• Injection, leucovorin calcium, per 50 mg (HCPCS:J0640)
• Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg (HCPCS:Q5119)
• Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less (HCPCS:96367)
• Injection, fluorouracil, 500 mg (HCPCS:J9190)
• Established patient office or other outpatient visit, 30-39 minutes (HCPCS:99214)
• Injection, fulvestrant, 25 mg (HCPCS:J9395)
• Flow cytometry technique for dna or cell analysis, each additional marker (HCPCS:88185)
• Administration of chemotherapy into vein, 1 hour or less (HCPCS:96413)
• Injection, pegfilgrastim, excludes biosimilar, 0.5 mg (HCPCS:J2506)
• Injection of drug or substance under skin or into muscle (HCPCS:96372)
• Injection, pegfilgrastim-apgf, biosimilar, (nyvepria), 0.5 mg (HCPCS:Q5122)
• Injection, irinotecan, 20 mg (HCPCS:J9206)
• Gammaglobulin (immune system protein) measurement (HCPCS:82784)
• Injection, magnesium sulfate, per 500 mg (HCPCS:J3475)
• Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a (HCPCS:G9678)
• Injection, etoposide, 10 mg (HCPCS:J9181)
• Ferritin (blood protein) level (HCPCS:82728)
• Injection, potassium chloride, per 2 meq (HCPCS:J3480)
• Iron level (HCPCS:83540)
• Iron binding capacity (HCPCS:83550)
• Established patient office or other outpatient visit, 40-54 minutes (HCPCS:99215)
• Cyclophosphamide, 100 mg (HCPCS:J9070)
• Administration of additional new drug or substance into vein, 1 hour or less (HCPCS:96417)
• Injection, carboplatin, 50 mg (HCPCS:J9045)
• Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg (HCPCS:J9201)
• Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less (HCPCS:96365)
• Injection, doxorubicin hydrochloride, 10 mg (HCPCS:J9000)
• Administration of chemotherapy into vein, each additional hour (HCPCS:96415)
• Injection, diphenhydramine hcl, up to 50 mg (HCPCS:J1200)
• Lactate dehydrogenase (enzyme) level (HCPCS:83615)
• Injection, cisplatin, powder or solution, 10 mg (HCPCS:J9060)
• Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96401)
• Infusion into a vein for therapy, prevention, or diagnosis, each additional hour (HCPCS:96366)
• Injection, zoledronic acid, 1 mg (HCPCS:J3489)
• Phosphate level (HCPCS:84100)
• Injection of additional new drug or substance into vein (HCPCS:96375)
• Infusion, normal saline solution , 1000 cc (HCPCS:J7030)
• Cyanocobalamin (vitamin b-12) level (HCPCS:82607)
• Infusion, normal saline solution, sterile (500 ml = 1 unit) (HCPCS:J7040)
• Established patient office or other outpatient visit, 20-29 minutes (HCPCS:99213)
• Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l (HCPCS:G0498)
• Beta-2 microglobulin (protein) level (HCPCS:82232)
• Administration of additional new drug or substance into vein using push technique (HCPCS:96411)
• Psa (prostate specific antigen) measurement, total (HCPCS:84153)
• Carcinoembryonic antigen (cea) protein level (HCPCS:82378)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 15-3 (HCPCS:86300)
• Unclassified drugs (HCPCS:J3490)
• New patient office or other outpatient visit, 45-59 minutes (HCPCS:99204)
• Infusion into a vein for hydration, 31-60 minutes (HCPCS:96360)
• Urinalysis, manual test (HCPCS:81002)
• Prealbumin (protein) level (HCPCS:84134)
• Blood test, thyroid stimulating hormone (tsh) (HCPCS:84443)
• Vitamin d-3 level (HCPCS:82306)
• Irrigation of implanted venous access drug delivery device (HCPCS:96523)
• Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle (HCPCS:96402)
• Infusion into a vein for hydration, each additional hour (HCPCS:96361)
• Uric acid level, blood (HCPCS:84550)
• Injection, fosnetupitant 235 mg and palonosetron 0.25 mg (HCPCS:J1454)
• Collection of blood sample from implanted device (HCPCS:36591)
• Initial hospital inpatient care per day, typically 70 minutes (HCPCS:99223)
• Application of on-body injector for under skin injection (HCPCS:96377)
• Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg (HCPCS:J3420)
• Immunologic analysis for detection of tumor antigen, quantitative; ca 125 (HCPCS:86304)
• New patient office or other outpatient visit, 60-74 minutes (HCPCS:99205)
• Drawing of blood for a medical problem (HCPCS:99195)
• Flow cytometry technique for dna or cell analysis, first marker (HCPCS:88184)
• Injection of drug or substance into vein (HCPCS:96374)
• Detection test by immunoassay technique for severe acute respiratory syndrome coronavirus (HCPCS:87426)
• Injection, furosemide, up to 20 mg (HCPCS:J1940)
• Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report (HCPCS:93000)
• Injection, methylprednisolone sodium succinate, up to 125 mg (HCPCS:J2930)
• Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromise (HCPCS:M0220)
• Administration of influenza virus vaccine (HCPCS:G0008)
• Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage (HCPCS:90694)
• Coronavirus vaccine 14 (HCPCS:91313)

The enumeration date for this NPI number is 7/5/2006 and was last updated on 3/24/2008.

Taxonomy Codes

The NPI record includes the healthcare provider taxonomy classification, state license number and state of licensure. The following information regarding the scope of practice of this provider is available: